Vitrafy Life Sciences Ltd.
VFY.AX
Australian Securities Exchange3.05
AUD
-0.07
- -
ISIN
AU0000361297
Return %
Stock
S&P500
1Y
117.86
21.04
3Y
54.04
70.88
5Y
54.04
73.53
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Brenton Michael Leslie Owens
- Sector
- Healthcare
- Industry
- Medical - Specialties
- Address
- Suite 2, Level 11, 385 Bourke Street Melbourne VIC Australia 3000
- IPO Date
- Nov 21, 2024
- Website
- vitrafy.com
- Similar Companies
- Business
- Vitrafy Life Sciences Ltd. engages in the development and commercialization of vertically integrated cryopreservation solutions for biomaterials, spanning hardware devices, software platforms, and related services. The company designs and manufactures smart cryopreservation equipment, including a Smart Cryopreservation Device, a Smart Thawing Device, and Smart Packaging solutions; it launches and maintains LifeChain, a cloud-based software platform that integrates AI, machine learning and IoMT capabilities to control, trace, track, and monitor the quality and supply-chain status of cryopreserved materials. Vitrafy provides application services that support human health and animal health applications, and offers AI-enabled software for quality management, data capture, and provenance across the cryopreservation lifecycle. The company operates across multiple sectors including human cell and gene therapies, blood product logistics, biobanking, animal genetics and reproduction, and aquaculture-related biotechnologies. Founding year and headquarters: founded in 2017; headquartered in South Melbourne, Victoria, Australia. Geographic operations encompass Australia with a focus on domestic markets and collaborations that extend to international partners. Subsidiaries and parent relationships are not disclosed in public materials, but the company maintains partnerships and collaboration agreements with CSL Innovation Pty Ltd, the US Army Institute of Surgical Research, Select Sires, Inc., and Huon Aquaculture Company Pty Ltd, indicating active engagement with strategic partners in both life sciences and animal biotechnology. Vitrafy’s business model emphasizes integrated hardware-software solutions, with a go-to-market that targets biobanks, clinical and research institutions, animal breeding programs, blood product organizations, and gene therapy developers. The company positioning centers on preserving biomaterial quality through end-to-end, trackable cryopreservation workflows and data-rich lifecycle management. Latest major changes include formation and expansion of partnerships and collaboration agreements in the past 1–2 years, potential product launches or enhancements to smart devices and LifeChain software, and ongoing initiatives to broaden applicability across human and animal health markets.